LEO

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Pharmaceutical, Health, Clinical Trials, Keratitis, American Academy of Dermatology, University, Paced Auditory Serial Addition Test, Leo Pharma, S. aureus, Week, Dermatitis, Infection, Food, Aes, American Academy, Atopic dermatitis, Skin, Gene expression, Staphylococcus, Staphylococcus aureus, Malignancy, Patient, AAD, Lower respiratory tract infection, LEO, Annual general meeting, European, Adolescence, PYE, University of Rochester Medical Center, Keratoconjunctivitis, Ageing, AD, FDA, Conjunctivitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Tralokinumab

The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • S. aureus is consistently found in the skin lesions of patients with AD and contributes to skin irritation and infections.
  • “In addition, the latest analysis of data from adolescents in the ECZTEND study shows the long-term safety and efficacy profile of Adbry.
  • Adtralza is approved for use in adults with moderate-to-severe AD in the U.S., United Arab Emirates, Switzerland, and Japan.

ALL.SPACE Delivers First Terminal to SES for Testing and Verification

Retrieved on: 
Thursday, March 16, 2023
Investment, GEO, OTA, U.S. Department of Defense Strategy for Operating in Cyberspace, MEO, Reading, O3b, ESA, SES, MPower, LEO, Communications satellite

WASHINGTON, March 16, 2023 (GLOBE NEWSWIRE) -- SATELLITE 2023 -- ALL.SPACE announced today delivery of its first smart terminal to SES for testing over its medium earth orbit systems -- O3b and O3b mPOWER.

Key Points: 
  • WASHINGTON, March 16, 2023 (GLOBE NEWSWIRE) -- SATELLITE 2023 -- ALL.SPACE announced today delivery of its first smart terminal to SES for testing over its medium earth orbit systems -- O3b and O3b mPOWER.
  • The milestone marks one of the final steps before the company officially launches its smart terminal to the defence and commercial market.
  • “Full performance, concurrent connections to multiple satellites in multiple orbits is now a reality,” said CEO and Founder John Finney.
  • ALL.SPACE's fully mil-standard smart terminal range will enable SES to fulfil the needs of both military and commercial customers in taking advantage of its O3b mPOWER system.

Sidus Space, Inc. Reports 2022 Financial Results - Annual Revenue up 418% and Annual Gross Profit up 492% as Compared To 2021

Retrieved on: 
Thursday, March 16, 2023
Software, Professional Services, Hardware, Data Management, Technology, Artificial Intelligence, Satellite, Data Analytics, Engineering, Aerospace, Manufacturing, Telecommunications, Constellation, Orbit, Sidus, Certification, Webcast, Artificial intelligence, International, TNO, United Netherlands (organization), Observation, AS9100, National Oceanographic Data Center, Freedom Lite SS-11 Skywatch, NASA, SpaceX, Mission control center, LEO, Bechtel, National Oceanic and Atmospheric Administration, Data collection, Intelligence, Dawn Aerospace, Critical, NOAA, Cryptocurrency, Video game, Communications satellite

(NASDAQ:SIDU), a Space-as-a-Service satellite company focused on commercial satellite design, manufacture, launch, and data collection, announced yesterday financial results for the year ended December 31, 2022 and provided company business updates.

Key Points: 
  • (NASDAQ:SIDU), a Space-as-a-Service satellite company focused on commercial satellite design, manufacture, launch, and data collection, announced yesterday financial results for the year ended December 31, 2022 and provided company business updates.
  • Sidus will webcast a conference call to discuss the results today at 9:00 am Eastern Time.
  • On a year-to-date basis, the Company has generated gross profit of 20% as compared to (26%) for the previous 2021 period.
  • Subsequent to the end of the quarter, the Company closed on an underwritten public offering, generating gross proceeds of $5.2 million.

Cobham Satcom to Roll Out O3b mPOWER Transportable Terminals for SES

Retrieved on: 
Tuesday, March 14, 2023
MEO, Communication, Radio, Business, O3b, Defense, COTP, Government, SES, O3b mPOWER, LEO, GEO, Government agency, MPower, Communications satellite, Geostationary orbit

The TACTICAL TRACKER Terminal serves the Government and Defense segment, while Government agencies, carriers, and enterprise customers utilize the EXPLORER terminals for service augmentation and restoration.

Key Points: 
  • The TACTICAL TRACKER Terminal serves the Government and Defense segment, while Government agencies, carriers, and enterprise customers utilize the EXPLORER terminals for service augmentation and restoration.
  • The O3b mPOWER system represents a tremendous step forward in communication satellite capabilities, providing unprecedented flexibility and throughput.
  • The new terminals expand Cobham Satcom's O3b mPOWER terminal portfolio, joining the recently certified Sea Tel 2400 Tri-band terminal for the energy market.
  • "We are pleased to provide new capabilities to SES for the growing COTP segment and to offer proven defense and enterprise solutions," noted Kirby Nell, VP of Business Development at Cobham Satcom.

Patricio Northland Named CEO of BeetleSat

Retrieved on: 
Tuesday, March 14, 2023
Technology, Networks, Telecommunications, Satellite, Falcon 9, Altitude, SSO, CubeSat, Eutelsat, Sun-synchronous orbit, Jerusalem Venture Partners, Executive, Communication, SpaceX, Israeli Nano Satellite Association, Growth, LEO, AT, Communications satellite

BeetleSat , formerly NSLComm, a fast-growing satellite technology company building the world’s first global LEO constellation optimized for premium point-to-point communications, today announced that Executive President Patricio Northland has been named Chief Executive Officer.

Key Points: 
  • BeetleSat , formerly NSLComm, a fast-growing satellite technology company building the world’s first global LEO constellation optimized for premium point-to-point communications, today announced that Executive President Patricio Northland has been named Chief Executive Officer.
  • His previous executive leadership roles include serving as CEO of Eutelsat Americas, CEO of Satelites Mexicanos S.A. de C.V. (SATMEX) and Chairman, President and CEO of AT&T Latin America.
  • View the full release here: https://www.businesswire.com/news/home/20230314006035/en/
    BeetleSat CEO Patricio Northland (Photo: Business Wire)
    As CEO of Eutelsat Americas, Northland led the company’s market entry and business in the region after architecting a successful merger with his prior company SATMEX in a deal valued at over $1.7B.
  • Leveraging his 20+ years of corporate leadership experience in the satellite technology and communications industries, Northland will lead BeetleSat through the next phases of its growth.

5G NTN Market Report 2022: Need for NTN in Evolution Toward 5G and 6G Presents Opportunities

Retrieved on: 
Tuesday, March 14, 2023
Hardware, Government, Defense, Telesat, 5G, Kilometres per hour, Aircraft, LTE, Component, GNB, Communication, EMBB, NTN, Node B, Local government in Canada, Rohde & Schwarz, Ericsson, MIMO, Growth, URLLC, LEO, Smartphone, MMTC, MediaTek, MEA, Automation, USD, G, Mobile phone, Communications satellite, Mining

The 5G NTN market is projected to grow from USD 3.2 billion in 2022 to USD 16.1 billion by 2027, at a CAGR of 38.2% during the forecast period.

Key Points: 
  • The 5G NTN market is projected to grow from USD 3.2 billion in 2022 to USD 16.1 billion by 2027, at a CAGR of 38.2% during the forecast period.
  • LEO is emerging as a preferred solution to develop a 5G NTN system to enhance network coverage and offer ample opportunities to bridge the connectivity divide.
  • The company has achieved a new 5G milestone by powering a smartphone with a 5G NTN connection for the first time.
  • With 5G NTN, eMBB services provide excellent broadband connectivity in rural and under-served areas on moving platforms, such as aircraft and vessels.

Active Electrical Scan Array Design Company Rapidtek to Showcase Latest Innovations at Satellite Show 2023

Retrieved on: 
Tuesday, March 14, 2023
Industrial Development Bureau, CubeSat, DC, National Central University, Hsinchu Taiwan Pavilion Expo Park, LEO, 3U, Research, Satellite, IDB, AESA, Taiwan Space Agency, Communications satellite

"We are thrilled to participate in Satellite Show 2023," said Arthur Wang, founder and CEO of Rapidtek.

Key Points: 
  • "We are thrilled to participate in Satellite Show 2023," said Arthur Wang, founder and CEO of Rapidtek.
  • "This event provides a unique opportunity for us to showcase our latest solutions, connect with industry experts and explore new business opportunities."
  • "We are confident that our solutions will appeal to a wide range of attendees at the Satellite Show," added Alex Chou, CTO of Rapidtek.
  • "We look forward to seeing you at Satellite Show 2023 and sharing the latest innovations from Rapidtek," concluded Arthur Wang, founder and CEO of Rapidtek.

LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team

Retrieved on: 
Tuesday, March 14, 2023
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Bispebjerg Hospital, Canadian industrial research and development organizations, University, Development, Dermatology, Atopic dermatitis, Skin, University of Copenhagen Faculty of Health and Medical Sciences, Patient, LEO, EVP, GLT, Research and development, Pharma, Drug development, Leo Pharma, Delgocitinib, Pharmaceutical industry, Management

To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.

Key Points: 
  • To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.
  • Jacob is an internationally recognized dermatologist and key opinion leader who will add his clinical experience and strong understanding of patients’ needs into LEO Pharma's drug development.
  • To support these two critical pillars, LEO Pharma today announced a split of its Research and Development organization into two distinct areas, both represented in the Global Leadership Team (GLT).
  • I am delighted to welcome Jacob to LEO Pharma and the Global Leadership Team and am confident that his experience will help spearhead our innovative portfolio.